Molecular Biosystems Inc.

Can Amersham Health convert a stodgy near-commodity business into a high value high growth proposition? It's the goal of many in vivo and in vitro diagnostics companies—but successes to date are few a

Small companies often have difficulty ensuring that customers really want their developments. By David Cassak If you don't know where you're going, any road will take you there." It's one of the given

Point Biomedical Corp. is using proprietary biodegradable polymers which are adjustable for in vivo residence time, biological reactivity and tissue integration properties. The company's particula

Given all the reasons that growth of the contrast media market could have flattened dramatically by now, its rise to about $3.5 billion in worldwide sales last year is remarkable. Once projected to re